TR200301208T2 - Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri. - Google Patents

Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.

Info

Publication number
TR200301208T2
TR200301208T2 TR2003/01208T TR200301208T TR200301208T2 TR 200301208 T2 TR200301208 T2 TR 200301208T2 TR 2003/01208 T TR2003/01208 T TR 2003/01208T TR 200301208 T TR200301208 T TR 200301208T TR 200301208 T2 TR200301208 T2 TR 200301208T2
Authority
TR
Turkey
Prior art keywords
conjugate
nublastin
methods
polymer conjugates
longer
Prior art date
Application number
TR2003/01208T
Other languages
English (en)
Inventor
W. Y. Sah Dinah
Blake Pepinsky R.
Ann Borjack-Sjodin Paula
S. Miller Stephan
Rossomando Anthony
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of TR200301208T2 publication Critical patent/TR200301208T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)

Abstract

Bir polialkilen glikol grubu içeren bir polimere birlesik olarak degisken neublastin polipeptidi içeren bir eslenik yapimi için uygun bir degisken neublastin polipeptidi tarif edilmektedir. Bu eslenik modifiye edilmemis veya vahsi-tip neublastin formlarina göre daha uzun süreli biyoyararlanima ve tercih edilen uygulamalarda daha uzun süreli biyolojik aktiviteye sahiptir. Bulusun eslenikleri tedavi uygulamalarinda ve ayni zamanda tedavi edici olmayan, ör., teshis, uygulamalarinda yararli bir sekilde kullanilabilir.
TR2003/01208T 2001-02-01 2002-01-25 Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri. TR200301208T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
TR200301208T2 true TR200301208T2 (tr) 2005-05-23

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2003/01208T TR200301208T2 (tr) 2001-02-01 2002-01-25 Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.

Country Status (36)

Country Link
EP (2) EP1862475A1 (tr)
JP (2) JP4259868B2 (tr)
KR (2) KR100960063B1 (tr)
CN (1) CN1500095B (tr)
AR (1) AR035077A1 (tr)
AT (1) ATE365748T1 (tr)
AU (1) AU2002247037B2 (tr)
BG (1) BG66393B1 (tr)
BR (1) BR0206852A (tr)
CA (1) CA2436407C (tr)
CY (1) CY1106886T1 (tr)
CZ (1) CZ20032080A3 (tr)
DE (1) DE60220879T2 (tr)
DK (1) DK1355936T3 (tr)
EA (1) EA009771B1 (tr)
EE (1) EE05537B1 (tr)
ES (1) ES2289091T3 (tr)
GE (1) GEP20063916B (tr)
HK (1) HK1057759A1 (tr)
HU (1) HU228973B1 (tr)
IL (2) IL156941A0 (tr)
IS (1) IS2867B (tr)
MX (1) MXPA03006805A (tr)
MY (1) MY143685A (tr)
NO (1) NO332150B1 (tr)
NZ (1) NZ527863A (tr)
PL (1) PL211162B1 (tr)
PT (1) PT1355936E (tr)
RS (1) RS50857B (tr)
SG (1) SG149685A1 (tr)
SI (1) SI1355936T1 (tr)
SK (1) SK288123B6 (tr)
TR (1) TR200301208T2 (tr)
UA (2) UA100967C2 (tr)
WO (1) WO2002060929A2 (tr)
ZA (1) ZA200305733B (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
EP1395279B1 (en) * 2001-03-28 2011-10-05 Biogen Idec MA Inc. Use of neublastin polypeptides for treating neuropathic pain
HUE028163T2 (en) * 2002-01-18 2016-11-28 Biogen Ma Inc Polyalkylene polymer compounds and their use
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
NZ574121A (en) 2003-04-18 2011-06-30 Biogen Idec Inc Polyethylene glycol-conjugated gylcosylated neublastin and uses thereof for treatment of pain
BRPI0411243A (pt) 2003-06-10 2006-07-11 Nsgene As método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ553431A (en) 2004-08-19 2010-04-30 Biogen Idec Inc Neublastin variants with decreased heparin binding
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
EP2142205B1 (en) * 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
PL2773438T5 (pl) * 2011-11-02 2022-01-17 F.Hoffmann-La Roche Ag Chromatografia przeciążenia i elucji
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
WO2002060929A2 (en) * 2001-02-01 2002-08-08 Biogen, Inc. Polymer conjugates of neublastin and methods of using same

Also Published As

Publication number Publication date
EA200300852A1 (ru) 2004-06-24
NO20033441D0 (no) 2003-08-01
IL156941A (en) 2008-11-03
DK1355936T3 (da) 2007-10-29
EE200300355A (et) 2003-10-15
CA2436407A1 (en) 2002-08-08
EE05537B1 (et) 2012-04-16
SI1355936T1 (sl) 2007-12-31
HK1057759A1 (en) 2004-04-16
EP1355936A2 (en) 2003-10-29
PL211162B1 (pl) 2012-04-30
EA009771B1 (ru) 2008-04-28
IS2867B (is) 2014-02-15
MXPA03006805A (es) 2003-11-13
CY1106886T1 (el) 2012-09-26
PL372101A1 (en) 2005-07-11
GEP20063916B (en) 2006-09-11
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
BG108111A (bg) 2004-12-30
ES2289091T3 (es) 2008-02-01
YU61003A (sh) 2006-05-25
CN1500095B (zh) 2010-06-16
ATE365748T1 (de) 2007-07-15
CZ20032080A3 (cs) 2003-10-15
UA82983C2 (ru) 2008-06-10
SK9712003A3 (en) 2004-01-08
EP1355936B1 (en) 2007-06-27
IS6879A (is) 2003-07-17
WO2002060929A2 (en) 2002-08-08
CN1500095A (zh) 2004-05-26
RS50857B (sr) 2010-08-31
KR100960063B1 (ko) 2010-05-31
NO20033441L (no) 2003-10-01
HUP0500637A2 (hu) 2005-09-28
AR035077A1 (es) 2004-04-14
DE60220879T2 (de) 2008-03-06
IL156941A0 (en) 2004-02-08
BG66393B1 (bg) 2013-11-29
UA100967C2 (ru) 2013-02-25
JP4423338B2 (ja) 2010-03-03
SK288123B6 (sk) 2013-09-03
WO2002060929A3 (en) 2003-03-06
AU2002247037B2 (en) 2007-08-16
NO332150B1 (no) 2012-07-09
NZ527863A (en) 2006-09-29
SG149685A1 (en) 2009-02-27
KR20080098662A (ko) 2008-11-11
CA2436407C (en) 2011-08-30
MY143685A (en) 2011-06-30
KR20030074766A (ko) 2003-09-19
PT1355936E (pt) 2007-09-28
HUP0500637A3 (en) 2010-01-28
HU228973B1 (en) 2013-07-29
BR0206852A (pt) 2005-05-03
JP4259868B2 (ja) 2009-04-30
DE60220879D1 (de) 2007-08-09
JP2005503763A (ja) 2005-02-10
ZA200305733B (en) 2005-02-23
KR100872807B1 (ko) 2008-12-09

Similar Documents

Publication Publication Date Title
TR200301208T2 (tr) Nublastin polimer eşlenikleri ve bunları kullanma yöntemleri.
LTPA2017030I1 (lt) Interferono beta-1A polimero konjugatai ir jų panaudojimas
DE60322339D1 (de) Bindungsproteine als biosensoren
LU92175I2 (fr) Lixisénatide
DE60332774D1 (de) Verbesserte sso7-polymerase-konjugat-proteine
DE60037450D1 (de) Funf-helix protein
DE60206512D1 (de) Rapanycin29-enole
IL201274A0 (en) Modified antibodies to prostate-specific membrane antigen and uses thereof
ATE424842T1 (de) Proteine der bcl-2-familie und fragmente davon, und ihre verwendung bei krebspatienten
CY1112682T1 (el) Ενεργες παραλλαγες της πρωτεϊνης προσδεσης il-18 και ιατρικες χρησεις αυτων
EP2386639A3 (en) Modified pore-forming protein toxins and use thereof
HUP0301581A2 (hu) Sejteken prezentált peptidek
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
TR200000416T2 (tr) Neisseria loctoferrin bağlayıcı protein.
DE60134408D1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
ITRM20010257A0 (it) Procedimento per la rinaturazione, idrolisi e produzione di proteine pr ricombinanti, composizioni e kit utilizzabili in tali procedimenti.
CY1108543T1 (el) Εμβολια dna που κωδικοποιουν βοηθητικες πρωτεϊνες του hiv